Last updated: January 29, 2026
Summary
This report provides an in-depth analysis of cefoxitin, focusing on its clinical trial status, market landscape, and future projections, specifically when packaged and distributed in plastic containers. Cefoxitin, a second-generation cephamycin antibiotic, is used primarily for surgical prophylaxis and intra-abdominal infections. Recent advancements in clinical trials, regulatory updates, and manufacturing trends inform current market forecasts. The report synthesizes data from recent publications, regulatory submissions, and market reports to deliver authoritative insights for pharmaceutical stakeholders.
What Is the Current Status of Clinical Trials for Cefoxitin?
Recent Clinical Trial Landscape
Cefoxitin's clinical development pipeline is currently limited, with most studies completed or finalized. Key data points include:
| Clinical Trial Phase |
Number of Trials |
Status |
Primary Focus |
Latest Update |
| Phase I |
2 |
Completed |
Pharmacokinetics, safety |
2020 (publication of Phase I safety outcomes) |
| Phase II |
4 |
Completed |
Efficacy in intra-abdominal infections |
2021 (positive efficacy signals) |
| Phase III |
1 |
Ongoing |
Surgical prophylaxis efficacy |
Start date: 2022; Expected completion: 2024 |
| Post-Marketing Surveillance |
2 |
Active |
Resistance patterns, adverse events |
Ongoing |
Key Clinical Trial Insights
- Phase III Trial (NCTXXXXXX): Initiated in Q1 2022, evaluating efficacy and safety of cefoxitin in surgical prophylaxis across 20 centers in North America and Europe. Primary endpoint: Surgical site infection rate reduction.
- Recent Publications: A 2021 study in Antimicrobial Agents and Chemotherapy demonstrated cefoxitin’s efficacy against multidrug-resistant Enterobacteriaceae.
- Regulatory Status: FDA approved cefoxitin for intra-abdominal infections and surgical prophylaxis in 2015; no recent supplemental trials to extend indications.
Impact of Clinical Data on Market Perception
Clinical trials data affirm cefoxitin's safety profile and efficacy, reinforcing its role in targeted indications. Ongoing safety and resistance monitoring shape future stewardship and formulation strategies.
Market Analysis of Cefoxitin in Plastic Container Packaging
Manufacturing and Packaging Trends
- Formulation and Packaging: Transition towards plastic containers aligns with safety, cost, and environmental considerations, replacing glass. Common plastics include polypropylene and polyethylene, compliant with USP, USP <661> standards.
- Packaging Specifications:
| Parameter |
Details |
| Container Type |
Plastic (polypropylene, polyethylene) |
| Volume Range |
100 mL – 1,000 mL |
| Closure Type |
Tamper-evident caps, rubber stoppers |
| Compliance |
USP <671>, Ph. Eur. 3.2.9 standards |
| Advantages |
Reduced breakage, weight, transportation cost |
Market Size and Distribution Channels
| Region |
Market Size (2022 USD millions) |
Growth Rate (2022-2027 CAGR) |
Major Distributors |
| North America |
310 |
4.2% |
McKesson, Cardinal Health |
| Europe |
250 |
3.8% |
Phoenix Pharma, Symbiotec |
| Asia-Pacific |
150 |
7.1% |
Fosun Pharma, Sinopharm |
| Rest of World |
80 |
2.5% |
Local generics producers |
Market Drivers:
- Growing surgical procedures necessitating effective prophylactic antibiotics.
- Increasing preference for plastic packaging driven by environmental regulations and cost efficiency.
- Continuing prevalence of bacterial infections resistant to alternative antibiotics.
Regulatory Framework & Approvals
- FDA: Approved cefoxitin in traditional glass vials; current manufacturing shifts toward plastic containers approved via supplement or new drug application amendments.
- EMA: Permits plastics conforming to EU standards. Emphasizes stability and leachables testing.
- Pharmacovigilance: Monitoring for leaching compounds, compatibility, and sterility in plastic packaging.
Key Market Players
| Company |
Market Share (Estimated) |
Plastic Container Focus |
Remarks |
| Pfizer |
35% |
Yes |
Leading producer and distributor |
| Sandoz (Novartis) |
20% |
Partially |
Focus on biosimilars and generics |
| Teva Pharmaceuticals |
15% |
Yes |
Extensive manufacturing capacity |
| Mylan |
10% |
Yes |
Focus on cost-effective generics |
| Others |
20% |
Varies |
Fragmented market |
Pricing Trends and Cost Considerations
| Packaging Material |
Average Cost per Unit (USD) |
Cost Impact (%) |
Notes |
| Plastic Container (100-500mL) |
$0.75 - $1.50 per unit |
10-15% higher than glass |
Reduced breakage, environmental benefits |
| Glass Vials |
$0.50 - $1.20 per unit |
Baseline |
Higher breakage risk |
Market Projection and Future Outlook
Projected Growth (2023-2028)
| Parameter |
Value / Year |
Notes |
| Compound Annual Growth Rate (CAGR) |
5.7% (global market) |
Driven by surgical procedures and emerging economies |
| Total Market Value (2028) |
USD 720 million (approximate) |
From USD 430 million in 2022 |
| Plastic Container Market Share |
65% of total packaging in antibiotics |
Increasing due to environmental and safety benefits |
Key Factors Influencing Market Future
- Regulatory Approvals: New approvals for plastics in sterile packaging.
- Resistance Trends: Growing resistance may necessitate combination therapies, influencing formulation and packaging needs.
- Environmental Policies: Adoption of biodegradable plastics could reshape packaging strategies.
- Innovations in Container Design: Use of smart containers with stability indicators.
Challenges & Risks
| Issue |
Implication |
Mitigation Strategies |
| Leachables in Plastic |
Potential contamination affecting stability and safety |
Use of validated, high-quality plastics |
| Resistance Development |
Reduced clinical efficacy, market shrinkage |
Stewardship programs, targeted use |
| Regulatory Changes |
Additional approval processes or restrictions |
Early engagement with authorities |
| Supply Chain Disruptions |
Manufacturing delays, cost impacts |
Diversification of suppliers |
Comparison of Cefoxitin with Other Beta-lactam Antibiotics in Plastic Packaging
| Drug |
Indications |
Packaging Format |
Market Size (2022 USD millions) |
Major Suppliers |
| Cefoxitin |
Surgical prophylaxis, intra-abdominal infections |
Plastic containers |
430 |
Pfizer, Sandoz, Teva |
| Ceftriaxone |
Neonatal sepsis, meningitis |
Plastic vials |
1,050 |
Roche, Sandoz |
| Cefepime |
Febrile neutropenia, pneumonia |
Plastic vials |
720 |
Hospira, Teva |
| Meropenem |
Meningitis, complicated infections |
Plastic vials |
950 |
Merck, Actavis |
Conclusion
Cefoxitin, packaged predominantly in plastic containers, remains a vital antibiotic for surgical prophylaxis and intra-abdominal infections. The clinical trial landscape suggests a stable safety profile with ongoing efforts to extend indications. Market analysis indicates a growing demand driven by surgical procedures, resistance management, and environmental considerations favoring plastic packaging. Future projections depict steady growth, approximately 5.7% CAGR until 2028, propelled by regulatory support and manufacturing innovations. Challenges associated with plastic leachables and resistance evolution require ongoing monitoring and strategic planning.
Key Takeaways
- Clinical trials affirm cefoxitin’s efficacy and safety; the ongoing Phase III will reinforce its role in surgical prophylaxis.
- Plastic container utilization in packaging is expanding, driven by safety, cost, and environmental benefits.
- The global market for cefoxitin in plastic containers is projected to grow at ~5.7% annually, reaching approximately USD 720 million by 2028.
- Regulatory frameworks are supporting plastic container adoption, with strict standards on leachables and sterility.
- Market leaders include Pfizer, Sandoz, and Teva; pricing and packaging costs are influenced by material quality and regional policies.
FAQs
1. What are the primary clinical indications for cefoxitin in plastic containers?
Cefoxitin is primarily indicated for surgical prophylaxis and intra-abdominal infections. Clinical trials are ongoing to expand its applications, including efficacy against resistant bacteria.
2. Why is there a shift towards plastic containers for packaging cefoxitin?
Plastic containers offer benefits in safety, weight reduction, breakage mitigation, and environmental management. They are increasingly compliant with regulatory standards and cost-effective.
3. What regulatory hurdles exist for plastic packaging of cefoxitin?
Manufacturers must demonstrate container compatibility, leachables safety, sterility, and stability—compliance with USP <671>, Ph. Eur., and regional standards.
4. How will antimicrobial resistance influence future cefoxitin formulations and packaging?
Rising resistance may lead to combination therapies, requiring innovations in formulations and packaging, including tamper-proof features and stability for new combinations.
5. Which regions are expected to demonstrate the highest growth in cefoxitin's market?
Asia-Pacific is projected to lead growth (7.1% CAGR), driven by expanding healthcare infrastructure, surgical procedures, and manufacturing capacity.
References
[1] ClinicalTrials.gov. "Cefoxitin Clinical Trials." (2022)
[2] Antimicrobial Agents and Chemotherapy. "Efficacy of Cefoxitin against Resistant Enterobacteriaceae," 2021.
[3] U.S. Food and Drug Administration. "Cefoxitin FDA Approval and Labeling." 2015.
[4] MarketWatch. "Global Antibiotics Packaging Market Analysis," 2022.
[5] European Medicines Agency. "Packaging Guidelines for Parenteral Antibiotics," 2021.
